Novo Nordisk Gains Regulatory Momentum for Weight-Loss Portfolio

EU approves higher Wegovy dose for obesity; Novo Nordisk progresses triple agonist trial and continues 15B DKK share buyback program.

Novo Nordisk has secured a significant regulatory advancement in Europe for its leading weight-management therapy, Wegovy. The European Commission's decision this week provides physicians with greater flexibility in treatment protocols. Concurrently, the pharmaceutical giant is advancing its drug development pipeline and continuing a substantial share repurchase initiative.

Share Buyback Program Progresses Alongside Pipeline News

Alongside the regulatory update, Novo Nordisk provided details on its ongoing capital return strategy. The company is currently executing a share repurchase program worth 15 billion Danish kroner, which commenced in February. As of February 13, the company had repurchased 1,750,000 B shares at an average price of 305.03 DKK, for a total value of 533.8 million DKK. This phase of the buyback program is scheduled to run until May 4.

In parallel, the company reported development progress for UBT251, a GLP?1/GIP/glucagon triple agonist candidate for the treatment of overweight and obesity. According to a ClinicalTrials.gov entry updated on February 17, a Phase 2 study has been initiated. The placebo-controlled, double-blind trial, which actually began on February 2, aims to enroll approximately 333 participants. Novo Nordisk licensed UBT251 from The United Laboratories in March 2025. Earlier Phase 1b data from China indicated an average weight reduction of 15.1% after 12 weeks in the highest dosage group.

European Regulators Approve Higher Wegovy Maintenance Dose

The European Commission granted approval on February 17 for a 7.2 mg maintenance dose of Wegovy (semaglutide). This authorization follows a positive opinion from the European Medicines Agency's scientific committee in December 2025. The new dosage option is intended for adults with obesity who require greater weight loss after the standard 2.4 mg maintenance dose.

While the higher dose is already practically achievable in the EU through three simultaneous 2.4 mg injections in a single weekly session, the company has also submitted an application for a dedicated 7.2 mg prefilled pen. Approval for this delivery device could see it become available later in the year.

Clinical Data Underpins Decision, UK Already On Board

The regulatory decision was supported by data from the STEP-UP study, which involved 1,407 participants with obesity without diabetes. When combined with lifestyle intervention, the average weight loss with the 7.2 mg dose was 21%, compared to approximately 2% in the placebo group. Notably, about one-third of participants achieved a weight loss of 25% or more.

Novo Nordisk also highlighted body composition findings, stating that 84% of the lost weight was fat mass, with muscle function preserved. The side effect profile remained consistent with this class of drug, primarily consisting of gastrointestinal issues such as nausea, diarrhea, and vomiting, as well as dysesthesia. These events were mostly mild to moderate and transient.

The 7.2 mg dose of Wegovy is already approved and available in the United Kingdom. Regulatory processes are ongoing in the United States and other markets.

Market Sentiment Remains Cautious Despite Progress

Despite this regulatory success, investor sentiment appears measured. Over a 30-day period, Novo Nordisk's shares have declined by nearly 19%. This movement suggests that while the long-term potential of the obesity treatment market remains a key focus, investors are also weighing near-term factors including valuation, competitive dynamics, and execution.